A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology (ACOG) guidelines for determining the ...

A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than ...

Replacing CA125 with the OVA1 multivariate index assay may better predict whether an ovarian mass is cancerous in premenopausal women and those with early-stage disease, according to data from a study ...

(Medical Xpress) -- Researchers at Vermillion, a medical diagnostics company have announced that clinical trials for its OVA1® blood test diagnostic tool have shown promising results. The tool, part ...

AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) today announced its OVA1® risk assessment test for ovarian cancer in women with pelvic masses is considered ...

- Milestone data announced during Ovarian Cancer Awareness Month, which demonstrates OVA1’s superior sensitivity of ovarian cancer risk detection in both Caucasian and African American women versus ...

MADISON, N.J. and AUSTIN, Texas, May 12, 2011 /PRNewswire/ -- A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of ...

MADISON, N.J. and FREMONT, Calif., March 9 OVA1(TM), the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for ...

A new study of OVA1 clinical performance in the presurgical detection of ovarian cancer, entitled "Clinical Performance of a Multivariate Index Assay For Detecting Early-Stage Ovarian Cancer," has ...

"We are pleased to expand the in-network coverage for OVA1 with the signing of these agreements," said Fred Ferrara, Chief Operating Officer of Vermillion, Inc. "These agreements increase coverage in ...

Vermillion, Inc.'s OVA1® has received a new statement on clinical validation and medical use issued by the Society of Gynecologic Oncology (SGO). Citing peer-reviewed publications from two pivotal ...

AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C., and US territories. AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s ...